Prospects for cannabinoid therapies in basal ganglia disorders. - Wikidata - awgldk - TriplyDB

Prospects for cannabinoid therapies in basal ganglia disorders.

Prospects for cannabinoid therapies in basal ganglia disorders.

http://www.wikidata.org/entity/Q37872326

about

Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway A restricted population of CB1 cannabinoid receptors with neuroprotective activity Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection Endocannabinoid signalling and the deteriorating brain Impaired neurogenesis by HIV-1-Gp120 is rescued by genetic deletion of fatty acid amide hydrolase enzyme.Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome Allelic series of Huntington's disease knock-in mice reveals expression discorrelates.Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors.Treatment with CB2 agonist JWH-133 reduces histological features associated with erectile dysfunction in hypercholesterolemic mice.Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease.The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG.Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias.Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?Endocannabinoid modulation of dopaminergic motor circuits.Cannabinoids: new promising agents in the treatment of neurological diseases.Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3.Singular Location and Signaling Profile of Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Dorsal Striatum.Brain cannabinoid receptor 2: expression, function and modulation.Cannabinoids for the Treatment of Movement Disorders.Vascular Dysfunction in a Transgenic Model of Alzheimer's Disease: Effects of CB1R and CB2R Cannabinoid Agonists.Does modulation of the endocannabinoid system have potential therapeutic utility in cerebellar ataxia?Cannabinoid CB(2) receptor attenuates morphine-induced inflammatory responses in activated microglial cells.AM1241 alleviates MPTP-induced Parkinson's disease and promotes the regeneration of DA neurons in PD mice.Themed issue on cannabinoids in biology and medicine.Pathway-Specific Control of Striatal Neuron Vulnerability by Corticostriatal Cannabinoid CB1 Receptors.Review of the neurological benefits of phytocannabinoids.

P2860

Q24623282-16E5D0F0-FA2A-4D40-9AC4-485E969D6948 Q28260273-41A5C611-C52C-4E14-8F2A-699CC0000AC6 Q29306901-533C7657-C631-497C-9F4C-F60AC0C0B6EA Q33730578-92D6560F-4CDF-45DB-BF3E-5FAAF257734C Q35499568-E54BDACC-54CC-48D5-B7F0-564BE8EA562E Q35754490-DAD1D9AE-9D66-4D60-A54C-6451FEC2C134 Q36124206-8BB2DD41-EA0E-44DC-9E6D-CC95E5CCE49F Q36719661-8298DC69-9E73-4108-8420-4F6898AF14BB Q36722685-3DD70EBE-08F7-49B6-82BB-CCC94325EDB1 Q37082410-AA6BA788-73EF-4E6D-99DF-CC515AFC3F6A Q37330515-166699C9-F76E-48DC-8714-6777750A97CE Q37512670-5CFE49E1-9B02-4A85-BCFD-9559D49C825F Q37553341-832FACBD-A1D7-4D04-8F5A-70A36635EA5E Q37577451-2E479C0D-9229-4E18-A8C2-4A1C96E45803 Q37637769-228E20E4-B573-4243-8B8A-CED74B7CD1FA Q38012845-6309B0F6-BB98-44AC-B7B3-8F327553BBAD Q38018946-D0326A66-95EB-460D-918A-834FE06C85E6 Q38269376-4F933FF9-2BDB-493F-A4BE-CCDD4F378022 Q38503842-F6934973-6A20-4C30-A12B-FD9652940F31 Q38817050-3B4F8B3E-CBA0-4EE9-86F7-807B8FF83DC6 Q39013000-D9628336-D8C9-462F-AFF3-A5CBFDAD0DE0 Q39075448-0ED805D7-E193-4787-A97C-4D08C24F4DC9 Q40701861-B52AB249-FE5D-43BC-946F-D6D09FF80626 Q41105693-3B0884E5-B504-4D60-89F5-D36D122EF0AC Q41761143-8A0C80A8-A301-48F3-B8BC-B2A02D7C189D Q42326753-4AEA463B-F4CF-4CCE-B0A8-0D0137B90904 Q42366580-EAD6DD9E-D3BC-4F6D-8226-1BC1DC6CE031 Q45323350-B58466F6-44A0-4F59-B0A6-D642EE935DF6 Q50092568-F4DFE3FA-94BE-4ABA-9FD5-EBB674E9054E Q55439675-C610B24D-4DCB-41E3-9C4A-599D44AAF675

P2860

Prospects for cannabinoid therapies in basal ganglia disorders.

http://www.wikidata.org/entity/Q37872326

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Prospects for cannabinoid therapies in basal ganglia disorders.

@en

Prospects for cannabinoid therapies in basal ganglia disorders.

@nl

type

label

Prospects for cannabinoid therapies in basal ganglia disorders.

@en

Prospects for cannabinoid therapies in basal ganglia disorders.

@nl

prefLabel

Prospects for cannabinoid therapies in basal ganglia disorders.

@en

Prospects for cannabinoid therapies in basal ganglia disorders.

@nl

P1433

Q37872326-0F99960D-0D63-49F0-A476-120F11A217CA

P1476

Q37872326-16AC1AC8-99AD-4099-A19F-B2A64337C053

P2093

Q37872326-2F63764C-18E9-45F8-A0EC-8E8F12BC902D

Q37872326-34904EB0-4A7A-437B-B0C4-B09C2CD205B9

Q37872326-3EABD50A-58B4-41D9-AA1E-1E002E9829A5

Q37872326-4F042E21-E676-4957-B276-745997987DF6

Q37872326-5585BABC-FEB3-42EF-8BA6-2E7EDB019E1E

Q37872326-8F1DF723-D6D6-4B4C-9004-2C09C5994B53

Q37872326-BCEE1509-7439-44F7-A4BB-7A7280E038F1

Q37872326-CA4F49C6-B133-40EB-80BE-43724A69F77D

Q37872326-CF680099-49D1-4945-B725-0DF0A355A471

Q37872326-F25DE958-F331-4F58-A68A-5DDAF95BA72D

P2860

Q37872326-00540824-751B-45FA-9842-00632629394E

Q37872326-01B2D158-1C5D-41E9-BE4A-062F5C865A03

Q37872326-0239505D-CE10-4902-8004-7AF7A51BA945

Q37872326-05EEA35C-B42E-45A5-8FC6-AFBC17F92948

Q37872326-067D8D75-2221-48E8-A53E-265DAB8663CE

Q37872326-0957D610-886F-45DB-B3F4-9071788A28FF

Q37872326-0D5F57FE-0A08-43D6-825B-2B922FC1D378

Q37872326-0D6E424C-76B1-4127-BEEF-0E405E303738

Q37872326-128DB157-81A5-46A5-8597-72E6B2CB31CF

Q37872326-13473B57-0239-4DED-8A5E-9DB46C3738CE

P304

Q37872326-406ECF14-3FC3-44E9-B372-2496F43EC6E1

P31

Q37872326-6BE2ABAD-5957-4F4F-80D2-C107C24DE64B

P356

Q37872326-9FC35397-E746-4A24-A892-7A5D423D018A

P407

Q37872326-EB3B6A5B-EB68-433A-9CFE-E2E230D0A0E0

P433

Q37872326-4E412ACB-0CBD-49FE-A720-1E2C74D4AB94

P478

Q37872326-B00EE426-E7A5-4038-8904-BF1BEB9B14B6

P50

Q37872326-6D2A70CF-907C-409B-B2A3-AEB895F9B13B

P577

Q37872326-52DC35D3-2AA6-4B8C-A5D5-FCD2ECC88B2A

P5875

Q37872326-101D4226-22BE-4E66-A706-74A8AC7FD405

P698

Q37872326-37AB33C3-E456-4AF9-BDE7-26D9937C5824

P921

Q37872326-6C72F082-A00C-4254-83BF-255A9597EF4D

P932

Q37872326-0B9BAB91-2A5B-4BAA-A471-CBC29A5BE984

P356

J.1476-5381.2011.01365.X

P1433

British Journal of Pharmacology

P1476

Prospects for cannabinoid therapies in basal ganglia disorders.

@en

P2093

Carmen Guaza

http://www.w3.org/2001/XMLSchema#string

Carmen Rodríguez-Cueto

http://www.w3.org/2001/XMLSchema#string

Cristina Palomo-Garo

http://www.w3.org/2001/XMLSchema#string

Javier Fernández-Ruiz

http://www.w3.org/2001/XMLSchema#string

José A Ramos

http://www.w3.org/2001/XMLSchema#string

Julián Romero

http://www.w3.org/2001/XMLSchema#string

Manuel Guzmán

http://www.w3.org/2001/XMLSchema#string

María Gómez-Cañas

http://www.w3.org/2001/XMLSchema#string

Miguel Moreno-Martet

http://www.w3.org/2001/XMLSchema#string

Sara Valdeolivas

http://www.w3.org/2001/XMLSchema#string

P2860

Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants

Evidence for a role of endocannabinoids, astrocytes and p38 phosphorylation in the resolution of postoperative pain

Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂

Evidence that MDMA ('ecstasy') increases cannabinoid CB2 receptor expression in microglial cells: role in the neuroinflammatory response in rat brain

COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord.

Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects.

Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription.

Effects of cannabinoids on energy metabolism.

Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.

P304

1365-1378

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1476-5381.2011.01365.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

163

http://www.w3.org/2001/XMLSchema#string

P50

Raphael Mechoulam

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51101010

http://www.w3.org/2001/XMLSchema#string

P698

21545415

http://www.w3.org/2001/XMLSchema#string

P921

P932

3165947

http://www.w3.org/2001/XMLSchema#string